Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis?

Anti-tumor necrosis factor (TNF) biological therapy has generally been accepted as a standard therapeutic option in inflammatory bowel disease (IBD) patient who are refractory to steroids or immunomodulators. However, the primary and secondary nonresponse rates to anti-TNF bioagents in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Guanglin, Florholmen, Jon, Goll, Rasmus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162116/
https://www.ncbi.nlm.nih.gov/pubmed/35663996
http://dx.doi.org/10.3389/fimmu.2022.881112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162116/
https://www.ncbi.nlm.nih.gov/pubmed/35663996
http://dx.doi.org/10.3389/fimmu.2022.881112

Ejemplares similares